tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Multiple Pulmonary Nodules D055613 2 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Retrognathia D063173 1 associated lipids
Leg Injuries D007869 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Pruritus Ani D011538 2 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Berney T et al. Islet of Langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations. 2004 Transplant. Proc. pmid:15194390
Tesi RJ et al. Conversion of pancreas transplants to FK 506 from CsA. 1995 Transplant. Proc. pmid:8539828
Weng LC et al. Association between use of FK506 and prevalence of post-transplantation diabetes mellitus in kidney transplant patients. 2014 Transplant. Proc. pmid:24656004
Wang SS et al. Clinical experience of tacrolimus with everolimus in heart transplantation. 2012 Transplant. Proc. pmid:22564581
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Latorre A et al. Clinical management of renal transplant patients with hepatitis C virus infection treated with cyclosporine or tacrolimus. 2002 Transplant. Proc. pmid:11959186
Fitzsimmons WE et al. Demographic considerations in tacrolimus pharmacokinetics. 1998 Transplant. Proc. pmid:9636552
Shapiro R et al. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. 1998 Transplant. Proc. pmid:9636557
González E et al. Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715911
Burke GW et al. Tacrolimus-related microangiopathy in kidney and simultaneous pancreas-kidney recipients: evidence of endothelin and cytokine involvement. 1998 Transplant. Proc. pmid:9532223
Ochiai M et al. Islet toxicity of FK506 measured in canine autografts. 1998 Transplant. Proc. pmid:9532224
Klintmalm GB et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679840
Ericzon BG et al. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. 1991 Transplant. Proc. pmid:1721273
Ye Q et al. Functional analysis of hamster kidney xenografts in the rat: possible functional incompatibility and adaptation of hamster kidney grafts in a xenogenic rat environment. 1996 Transplant. Proc. pmid:8623350
Gentil MA et al. Effect of new immunosuppressive regimens on cost of renal transplant maintenance immunosuppression. 2005 Transplant. Proc. pmid:15866631
Shimizu T et al. Risk factors of acute tacrolimus nephrotoxicity in renal allografts. 2000 Transplant. Proc. pmid:11119998
Garcia-Donaire JA et al. Tacrolimus as basic immunosuppression in pregnancy after renal transplantation. A single-center experience. 2005 Transplant. Proc. pmid:16386528
Argudo A et al. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. 2015 Transplant. Proc. pmid:26518936
Cuñetti L et al. Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay. 2018 Transplant. Proc. pmid:29579828
Tarasewicz A et al. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. 2009 Transplant. Proc. pmid:19917366
Mueller AR et al. Influence of immunosuppression on patient outcome after liver transplantation. 1998 Transplant. Proc. pmid:9636608
Donnelly JG and Soldin SJ Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. 1991 Transplant. Proc. pmid:1721305
Kawauchi M et al. Cardiac xenotransplantation from pig to Japanese monkey with splenectomy, tacrolims, filtration plasmapheresis, and nafamstat mesilate. 1994 Transplant. Proc. pmid:7518105
Falkiewicz K et al. Influence of vitamin D receptor gene polymorphisms on secondary hyperparathyroidism and bone density after kidney transplantation. 2005 Transplant. Proc. pmid:15848611
Oppenheimer F Steroid withdrawal in renal transplant recipients. 2000 Transplant. Proc. pmid:10686314
Platz KP et al. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. 1995 Transplant. Proc. pmid:7533357
Hairhara Y et al. Effect of fluconazole on blood levels of tacrolimus. 1999 Transplant. Proc. pmid:10578284
Kantarci G et al. Effects of different calcineurin inhibitors on sex hormone levels in transplanted male patients. 2004 Jan-Feb Transplant. Proc. pmid:15013339
Tamura A et al. Combination effect of tacrolimus and FTY720 in liver transplantation in rats. 1999 Transplant. Proc. pmid:10578290
Kolonko A et al. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation. 2011 Transplant. Proc. pmid:21996198
Abu-Elmagd K et al. Management of intestinal transplantation in humans. 1992 Transplant. Proc. pmid:1376523
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Woodle ES et al. FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. 1991 Transplant. Proc. pmid:1721337
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
Wilson C et al. Evaluation of daclizumab to reduce delayed graft function in non-heart-beating renal transplantation: a prospective, randomized trial. 2005 Transplant. Proc. pmid:15919462
Weimer R et al. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. 2005 Transplant. Proc. pmid:15919463
Kawano K et al. Protective effect of FK 506 on hepatic injury following cold ischemic preservation and transplantation: influence on hepatic microcirculation. 1995 Transplant. Proc. pmid:7533410
Viganò J et al. The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series. 2008 Jul-Aug Transplant. Proc. pmid:18675099
Varo E et al. Cardiovascular risk factors in liver allograft recipients: relationship with immunosuppressive therapy. 2002 Transplant. Proc. pmid:12176481
de Oliveira Clark RM et al. Evaluation of hemodynamic, metabolic, and electrolytic changes after graft reperfusion in a porcine model of intestinal transplantation. 2010 Jan-Feb Transplant. Proc. pmid:20172287
Larriba J et al. Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients. 2010 Jan-Feb Transplant. Proc. pmid:20172323
Cicero A and Lappin JA Pancreas transplantation: experience at University of Texas, Houston. 2010 Jan-Feb Transplant. Proc. pmid:20172339
Odoul F et al. Massive ingestion of tacrolimus in a young liver transplant patient. 1998 Transplant. Proc. pmid:9865375
Cronin DC et al. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. 1997 Feb-Mar Transplant. Proc. pmid:9123010
Rossi G et al. Results of orthotopic liver-small bowel transplantation in the pig using different immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907932
Platz KP et al. Immunosuppressive power and limitations of FK 506 for prevention and treatment of graft-vs-host disease after small bowel transplantation. 1996 Transplant. Proc. pmid:8907933
Todo S et al. Clinical small bowel or small bowel plus liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721369
Tzakis AG et al. Use of FK 506 in pediatric patients. 1991 Transplant. Proc. pmid:1703353
Morphopathological findings of renal allografts under FK 506 therapy. Japanese FK 506 Study Group. 1994 Transplant. Proc. pmid:7520614
Imanishi M et al. Induction of tolerance by intrathymic injection of donor bone marrow cells in the rat: simultaneous heart and skin allograft model. 1994 Transplant. Proc. pmid:7520615
Mange KC and Bloom RD Rates of acute rejection by recipient race and type of calcineurin inhibitor with mycophenolate mofetil. 2002 Transplant. Proc. pmid:12493393
Domenech N et al. Neither acute rejection nor immunosuppressant drug therapy (cyclosporine or tacrolimus) correlates with expression of either CD40 or CD154 on peripheral blood cells among human cardiac transplant patients. 2003 Transplant. Proc. pmid:12962873
Wayman MR et al. Two-year outcome in renal allograft recipients comparing neoral-led with tacrolimus-led therapy. 2002 Transplant. Proc. pmid:12176526
Sahutoglu T et al. Tac-MMF Versus CsA-MMF/CsA-AZA-Based Regimens in Development of De Novo Complement-Binding Anti-HLA Antibodies After Kidney Transplantation. 2017 Transplant. Proc. pmid:28340811
Marcus EA et al. Successful term pregnancy in an intestine-pancreas transplant recipient with chronic graft dysfunction and parenteral nutrition dependence: a case report. 2015 Transplant. Proc. pmid:25724255
Kaufman DB et al. Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy. 1999 Feb-Mar Transplant. Proc. pmid:10083261
San Miguel C et al. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital. 2015 Transplant. Proc. pmid:26518930
Miura K et al. Development of the Intestinal Transplantation Model With Major Histocompatibility Complex Inbred CLAWN Miniature Swine. 2016 Transplant. Proc. pmid:27320612
Guo Z et al. Leflunomide, a potential immunosuppressant for pancreatic islet transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123314
Jiang Y et al. Dyslipidemia in human kidney transplant recipients receiving cyclosporine and tacrolimus is associated with different expression of CD36 on peripheral blood monocytes. 2011 Transplant. Proc. pmid:21693242
DiMartini A et al. Psychiatric morbidity in liver transplant patients. 1991 Transplant. Proc. pmid:1721399
Golling M et al. Tacrolimus reduction improves glucose metabolism and insulin secretion after liver transplantation. 1996 Transplant. Proc. pmid:8962234
Lopez OL et al. Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721400
Moutabarrik A et al. Effect of FK 506 and cyclosporine on the expression of IL-6 and its receptor on stimulated monocytes. 1993 Transplant. Proc. pmid:7685949
Ochiai T et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. 1989 Transplant. Proc. pmid:2468228
Takaya S et al. Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. 1993 Transplant. Proc. pmid:7685953
Masaki Y et al. Microchimerism and rat small bowel transplantation combined with donor-type bone marrow cells. 1996 Transplant. Proc. pmid:8769154
Yasunami Y et al. Effects of a novel immunosuppressive agent, FK-506, on islet allograft survival in the rat. 1989 Transplant. Proc. pmid:2468234
Schweizer RT and Meisterling LD Tolerability of mycophenolate mofetil in organ transplant recipients. 2001 Transplant. Proc. pmid:11377540
Bhagavati S et al. Chronic sensorimotor polyneuropathy associated with tacrolimus immunosuppression in renal transplant patients: case reports. 2007 Transplant. Proc. pmid:18089409
Pham SM et al. Sirolimus and tacrolimus in clinical cardiac transplantation. 2002 Transplant. Proc. pmid:12176597
Langrehr JM et al. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial. 2001 Transplant. Proc. pmid:11377549
Uber PA et al. Steroid weaning in heart transplantation is associated with decreased B-type natriuretic peptide: surrogate evidence for cardiac adaptation. 2002 Transplant. Proc. pmid:12176598
Ciancio G et al. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267169
Vincenti F Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial. 2001 Feb-Mar Transplant. Proc. pmid:11267172
Alberti D et al. Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723310
Gridelli B et al. Frequency of switch from cyclosporine to FK 506 before and after Neoral use in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723311
Lagget M et al. Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients. 1998 Transplant. Proc. pmid:9723312
Joo DJ et al. Comparison of the affinity column-mediated immunoassay and microparticle enzyme immunoassay methods as a tacrolimus concentration assay in the early period after liver transplantation. 2010 Transplant. Proc. pmid:21168645
Valdivia LA et al. Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721432
Kawano K et al. FK506 reduces oxidative hepatic injury following cold ischemic preservation and transplantation. 1996 Transplant. Proc. pmid:8658938
Ochiai T et al. Prolongation of canine renal allograft survival by treatment with FK-506. 1987 Transplant. Proc. pmid:2445075
Koc-Zorawska E et al. Vascular adhesion protein-1, a novel molecule, in kidney and heart allograft recipients. 2013 Transplant. Proc. pmid:23769096
Filler G et al. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. 2004 Transplant. Proc. pmid:15251324
Shokouh-Amiri MH et al. The importance of early prevention of renal dysfunction in liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267345
García González M et al. Reversal of QT interval electrocardiographic alterations in cirrhotic patients undergoing liver transplantation. 1999 Transplant. Proc. pmid:10500620
Hirata Y et al. Antibody Drug Treatment for Steroid-Resistant Rejection After Pediatric Living Donor Liver Transplantation: A Single-Center Experience. Transplant. Proc. pmid:29407332
Falconer SJ et al. Early or Late Conversion From Tac-BD to Tac-BD in Renal Transplantation: When is the Right Time? Transplant. Proc. pmid:26293044
Nossal GJ Summary of the First International FK 506 Congress: perspectives and prospects. 1991 Transplant. Proc. pmid:1721464
Sessa A et al. Cardiovascular risk factors in renal transplant patients after switch from standard tacrolimus to prolonged-release tacrolimus. 2012 Transplant. Proc. pmid:22974866
Haba T et al. Pathological and immunohistochemical examination in the rat treated with FK 506. 1991 Transplant. Proc. pmid:1714649
Bozkaya G et al. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients. 2008 Jan-Feb Transplant. Proc. pmid:18261573
Alagoz S et al. Gangliocytoma Presenting With Tacrolimus Neurotoxicity in a Renal Transplant Recipient: Case Report. 2016 Transplant. Proc. pmid:27932167
Kinukawa T et al. Long-term comparison of tacrolimus and cyclosporine-based immunosuppression in kidney recipients with grafts from non-heart-beating cadaver donor. 1998 Transplant. Proc. pmid:9636498
Alak AM and Moy S Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. 1997 Transplant. Proc. pmid:9270821
Deleuze S et al. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine? 2006 Transplant. Proc. pmid:16980075
Badiou S et al. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? 2006 Transplant. Proc. pmid:16980076
Flavin T et al. Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. 1991 Transplant. Proc. pmid:1703701
Nielsen FT et al. Nephrotoxity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. 1994 Transplant. Proc. pmid:7527946
Jiang H et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703702